• Opdivo (nivolumab, Bristol-Myers Squibb) is approved for the treatment of patients with squamous cell non-small cell lung cancer (NSCLC) who have relapsed on platinum-based chemotherapy. Based on the clinical trial that served as the basis for approval, Opdivo did not stratify response rates based on PD-L1 levels, and the approved label does not have a biomarker requirement.
  • Is There a Breaking Point for Immunotherapy Costs?

    by Debbie Warner  |  Jul 1, 2015
    Value was an overarching theme at ASCO 2015 and has been a topic of ongoing focus, as have been the burgeoning pipeline of immunotherapy agents, with the recently launched PD-1 inhibitors, Opdivo® (nivolumab, Bristol Myers Squibb) and Keytruda® (pembrolizumab, Merck), being the highlights of ASCO 2015. Presenter Leonard Saltz, M.D. of Memorial Sloan Kettering praised the clinical value of an Opdivo + Keytruda combination as being “truly, truly remarkable,” but he added that with the combination costing nearly $300,000 (if continued for 11 months) “these drugs cost too much –unsustainable.” While Dr. Saltz is an unabashed critic of cancer drug prices, $300,000 would give most people pause.
More than one Google Analytics scripts are registered. Please verify your pages and templates.